Literature DB >> 12827261

[MR imaging of prostate cancer].

A Heuck1, J Scheidler, B Sommer, A Graser, U G Müller-Lisse, J Massmann.   

Abstract

PURPOSE: Accurate diagnosis and staging of prostate cancer (PC) is developing into an important health care issue in light of the high incidence of PC and the improvements in stage-adapted therapy. The purpose of this paper is to provide an overview on the current role of MR imaging and MR spectroscopy in the diagnosis and staging of PC.
MATERIAL AND METHODS: Pertinent literature was searched and evaluated to collect information on current clinical indications, study techniques, diagnostic value, and limitations of magnetic resonance imaging and spectroscopy.
RESULTS: Major indications for MR imaging of patients with suspected PC are to define tumor location before biopsy when clinical or TRUS findings are inconclusive, and to provide accurate staging of histologically proven PC to ascertain effective therapy. Current MR imaging techniques for the evaluation of PC include multiplanar high-resolution T2-weighted FSE and T1-weighted SE sequences using combined endorectal and phased-array coils. Using these techniques, the reported accuracy of MR imaging for the diagnosis of extracapsular tumor extension ranges between 82 and 88% with sensitivities between 80 and 95%, and specificities between 82 and 93%. Typical MR findings of PC in different stages of disease, as well as diagnostic problems, such as chronic prostatitis, biopsy-related hemorrhage and therapy-related changes of prostatic tissue are discussed. In addition, the current perspectives and limitations of MR spectroscopy in PC are summarized.
CONCLUSIONS: Current MR imaging techniques provide important diagnostic information in the pretherapeutic workup of PC including a high staging accuracy, and is superior to TRUS.

Entities:  

Mesh:

Year:  2003        PMID: 12827261     DOI: 10.1007/s00117-003-0906-7

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  15 in total

Review 1.  Individualized radiotherapy by combining high-end irradiation and magnetic resonance imaging.

Authors:  Stephanie E Combs; Fridtjof Nüsslin; Jan J Wilkens
Journal:  Strahlenther Onkol       Date:  2016-02-06       Impact factor: 3.621

2.  Reproducibility of image interpretation in MRI of the prostate: application of the sextant framework by two different radiologists.

Authors:  Ullrich Mueller-Lisse; Ulrike Mueller-Lisse; Juergen Scheidler; Gerhardt Klein; Maximilian Reiser
Journal:  Eur Radiol       Date:  2005-04-20       Impact factor: 5.315

Review 3.  [Diffusion-weighted MRI of the prostate].

Authors:  U G Mueller-Lisse; U L Mueller-Lisse; P Zamecnik; H-P W Schlemmer; M K Scherr
Journal:  Radiologe       Date:  2011-03       Impact factor: 0.635

4.  Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range.

Authors:  Robert V Mulkern; Agnieszka Szot Barnes; Steven J Haker; Yin P Hung; Frank J Rybicki; Stephan E Maier; Clare M C Tempany
Journal:  Magn Reson Imaging       Date:  2006-02-20       Impact factor: 2.546

5.  Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer.

Authors:  Bernhard Scher; Michael Seitz; Wolfram Albinger; Reinhold Tiling; Michael Scherr; Hans-Christoph Becker; Michael Souvatzogluou; Franz-Josef Gildehaus; Hans-Jürgen Wester; Stefan Dresel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-24       Impact factor: 9.236

Review 6.  [Imaging modalities for primary diagnosis and staging of prostate cancer].

Authors:  U G Mueller-Lisse; K Miller
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

7.  Carr-Purcell-Meiboom-Gill imaging of prostate cancer: quantitative T2 values for cancer discrimination.

Authors:  Joseph R Roebuck; Steven J Haker; Dimitris Mitsouras; Frank J Rybicki; Clare M Tempany; Robert V Mulkern
Journal:  Magn Reson Imaging       Date:  2008-09-26       Impact factor: 2.546

8.  [Prostate cancer].

Authors:  T Franiel; N Eckardt; M Waginger; M Horstmann
Journal:  Radiologe       Date:  2014-05       Impact factor: 0.635

Review 9.  [Oncologic screening with whole-body MRI: possibilities and limitations].

Authors:  J F Schäfer; A Fischmann; M Lichy; J Vollmar; M Fenchel; C D Claussen; H-P Schlemmer
Journal:  Radiologe       Date:  2004-09       Impact factor: 0.635

10.  [Imaging procedures to diagnose prostate cancer].

Authors:  M Seitz; B Scher; M Scherr; D Tilki; B Schlenker; C Gratzke; A Schipf; P Stanislaus; U Müller-Lisse; O Reich; C Stief
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.